Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07240805 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Digital Health Technologies for Progressive Supranuclear Palsy and Dementia With Lewy Bodies

StatusNot Yet Recruiting
PhaseNot specified
SponsorBioSensics
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 5 months later Jul 1, 2028 → Dec 1, 2028
See other at-risk trials from BioSensics

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Jun 15, 2026 to Jan 15, 2027 Show 5 more changesShow less
    • Primary endpoints: details revised at 1 of 8 entries
    • Primary completion pushed from Jul 1, 2028 to Dec 1, 2028
    • Eligibility criteria expanded, about 7 words
    • Secondary endpoints: details revised at 4 of 5 entries
    • Publications: details revised at 2 of 2 entries
  2. Site contacts updated at 1 of 2 sitesv4
  3. Site contacts updated at 1 of 2 sitesv3
  4. Primary completion date: Jan 1, 2028 to Jul 1, 2028
    • Start date: Jan 1, 2026 to Jun 15, 2026
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
BioSensics
8 trials monitored
See 1 trial at risk
Dementia
1,978 trials monitored
See 106 trials at risk
Progressive supranuclear palsy (PSP), mild cognitive impairment with Lewy bodies (MCI-LB), and Dementia with Lewy Bodies (DLB) are severe neurodegenerative diseases that cause significant motor impairment impacting daily function. Researchers at BioSensics, Johns Hopkins School of Medicine, Massachusetts General Hospital and their collaborators aim to conduct an analytical and clinical validation of wearable-based digital health technologies for monitoring upper and lower limb function in PSP, MCI-LB and DLB that could enable frequent, at-home monitoring and be incorporated into future clinical trials.
Trial Details
NCT Number NCT07240805
Lead Sponsor BioSensics
Collaborators: National Institute on Aging (NIA), Johns Hopkins University, Massachusetts General Hospital
Conditions
(from sponsor)		 Progressive Supranuclear Palsy(PSP), Dementia With Lewy Bodies (DLB), PSP, Lewy Body Dementia (LBD), Lewy Body Disease
Related terms Lewy Body Disease, Supranuclear Palsy, Progressive
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov